Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

HUTCHMED DRC

Healthcare US HCM

10.87USD
-0.3(2.69%)

Last update at 2026-06-05T20:00:00Z

Day Range

10.7111.06
LowHigh

52 Week Range

10.6821.92
LowHigh

Fundamentals

  • Previous Close 11.17
  • Market Cap3270.00M
  • Volume120817
  • P/E Ratio31.73
  • Dividend Yield-%
  • EBITDA26.58M
  • Revenue TTM838.00M
  • Revenue Per Share TTM4.93
  • Gross Profit TTM -271.58700M
  • Diluted EPS TTM0.60

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -410.42200M -215.74000M -189.73400M -141.10500M -86.65500M
Minority interest -0.44900M -27.60700M 34.83M 24.89M 23.26M
Net income -410.13900M -227.65800M -194.56300M -144.37900M -74.80500M
Selling general administrative 92.17M 89.30M 50.02M 39.21M 30.91M
Selling and marketing expenses 43.93M 37.83M 11.33M 13.72M 17.74M
Gross profit 115.31M 97.89M 39.46M 44.74M 70.17M
Reconciled depreciation 8.66M 7.19M 6.06M 4.94M 3.59M
Ebit -409.77000M -336.45800M -188.94700M -145.01900M -85.64600M
Ebitda -401.10600M -329.26800M -182.88600M -135.13300M -82.05600M
Depreciation and amortization 8.66M 7.19M 6.06M 9.89M 3.59M
Non operating income net other - - - - -
Operating income -409.77000M -336.45800M -188.94700M -145.01900M -92.64100M
Other operating expenses 834.10M 684.45M 424.64M 349.91M 304.95M
Interest expense 0.65M 0.59M 0.79M 1.03M 1.01M
Tax provision -0.28300M 11.92M 4.83M 3.27M 3.96M
Interest income 9.60M 2.08M 3.24M 4.94M 5.98M
Net interest income 8.95M 1.48M 2.45M 3.91M 4.97M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.28300M 11.92M 4.83M 3.27M 3.96M
Total revenue 426.41M 356.13M 227.98M 204.89M 214.11M
Total operating expenses 523.00M 426.21M 236.12M 189.76M 161.01M
Cost of revenue 311.10M 258.23M 188.52M 160.15M 143.94M
Total other income expense net -0.65200M 120.72M -0.78700M 3.91M 5.99M
Discontinued operations - - - - -
Net income from continuing ops -360.38600M -167.04100M -115.51700M -103.67900M -71.28600M
Net income applicable to common shares -360.83500M -194.64800M -125.73000M -106.02400M -74.80500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1279.77M 1029.44M 1372.66M 724.12M 465.12M
Intangible assets - - 0.16M 0.23M 0.28M
Earning assets - - - - -
Other current assets 9.79M 152.20M 81.04M 29.15M 42.24M
Total liab 536.39M 392.57M 333.15M 205.17M 152.22M
Total stockholder equity 730.54M 610.37M 986.89M 484.12M 288.01M
Deferred long term liab - - - 1.17M 0.18M
Other current liab 273.98M 18.17M 17.19M 0.37M 0.45M
Common stock 87.13M 86.48M 86.45M 72.77M 66.69M
Capital stock 87.13M 86.48M 86.45M 72.77M 66.69M
Retained earnings -870.86900M -971.48100M -610.32800M -415.59100M -289.73400M
Other liab - 15.37M 14.33M 13.27M 8.67M
Good will 3.06M - 3.38M 3.31M 3.11M
Other assets 0.00000M 31.11M 27.41M 18.15M 24.21M
Cash 283.59M 313.28M 377.54M 235.63M 121.16M
Cash and equivalents - - - - -
Total current liabilities 403.03M 353.90M 311.66M 158.40M 113.10M
Current deferred revenue 57.64M - 226.38M 123.63M 85.48M
Net debt -197.45800M -289.97800M -343.47600M -199.92000M -88.07400M
Short term debt 35.08M 264.62M 26.91M 2.79M 3.22M
Short long term debt 31.16M 0.00000M 26.91M - -
Short long term debt total 86.13M 23.30M 34.07M 35.71M 33.08M
Other stockholder equity 1522.45M 1495.37M 1510.77M 826.93M 511.06M
Property plant equipment - 84.67M 53.15M 32.19M 26.37M
Total current assets 1096.84M 839.89M 1212.08M 530.74M 317.02M
Long term investments - - - - 98.94M
Net tangible assets - 610.37M 983.35M 480.58M 284.62M
Short term investments 602.75M 317.72M 634.16M 199.55M 96.01M
Net receivables 150.46M 97.99M 83.58M 46.65M 41.41M
Long term debt 48.19M 18.10M 0.00000M 26.86M 26.82M
Inventory 50.26M 56.69M 35.76M 19.77M 16.21M
Accounts payable 36.33M 71.11M 41.18M 31.61M 23.96M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -8.16300M - - 4.48M -4.00000M
Additional paid in capital - - - - -
Common stock total equity - - - 72.77M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 11.61M 333.46M 639.00M 203.06M 113.48M
Deferred long term asset charges - - - - -
Non current assets total 182.93M 189.56M 160.59M 193.38M 148.10M
Capital lease obligations 6.79M 5.20M 7.16M 8.85M 6.26M
Long term debt total - - - - 29.87M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 296.59M -275.49400M -125.44100M 119.03M 43.75M
Change to liabilities 30.32M 20.64M 7.49M -2.37300M 1.02M
Total cashflows from investing activities 296.59M -306.32000M -125.44100M 119.03M 43.75M
Net borrowings -9.17000M -0.57900M -0.57900M -0.11600M -4.62700M
Total cash from financing activities -82.76300M 650.03M 296.43M -1.49300M -8.23100M
Change to operating activities 64.04M 63.46M 30.10M 22.96M 7.18M
Net income -360.38600M -167.04100M -115.51700M -103.67900M -71.28600M
Change in cash -64.26400M 141.91M 114.47M 35.12M 0.77M
Begin period cash flow 377.54M 235.63M 121.16M 86.04M 85.27M
End period cash flow 313.28M 377.54M 235.63M 121.16M 86.04M
Total cash from operating activities -268.59900M -204.22300M -62.06600M -80.91200M -32.84700M
Issuance of capital stock 0.17M 717.32M 318.93M 0.25M 3.87M
Depreciation 8.66M 7.19M 6.06M 4.94M 3.59M
Other cashflows from investing activities - -15.00000M -15.00000M 127.59M 50.12M
Dividends paid -87.43600M -99.74400M - 28.14M 24.90M
Change to inventory -21.21300M -16.00200M -3.62300M -4.21500M -0.55700M
Change to account receivables -14.45100M -35.63400M -4.69300M -1.20900M -1.56400M
Sale purchase of stock -48.08400M -27.30900M -12.90400M -0.34600M -5.45100M
Other cashflows from financing activities 79.51M 159.51M -9.59600M 25.52M 48.25M
Change to netincome 24.85M -49.26700M 28.29M 3.87M 31.13M
Capital expenditures 36.66M 16.76M 19.58M 8.56M 6.36M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 58.70M 32.46M 29.27M 16.11M 6.96M
Stock based compensation 30.59M 41.99M 19.64M 11.59M 10.13M
Other non cash items -6.16700M -3.68300M -2.07700M 0.39M 0.08M
Free cash flow -305.26300M -220.97900M -81.64600M -89.47700M -39.21100M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
HCM
HUTCHMED DRC		 -0.3 2.69% 10.87 31.73 - 3.74 4.18 2.75 34.30
ZTS
Zoetis Inc		 -0.08 0.10% 79.44 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -1.13 3.48% 31.32 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -5.4 3.30% 158.31 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.13 0.32% 40.45 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

HUTCHMED DRC

Cheung Kong Center, Hong Kong, Hong Kong

Key Executives

Name Title Year Born
Mr. Chi Keung To ACGI, B.Sc., BSc, M.B.A., MBA Exec. Chairman 1952
Dr. Weiguo Su B.Sc., Ph.D. CEO, Chief Scientific Officer & Exec. Director 1957
Mr. Chig Fung Cheng BEc, CA CFO & Exec. Director 1967
Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, EdM, Solicito Company Sec. & Non-Exec. Director 1952
Dr. Karen Jane Atkin Exec. VP & COO 1966
Mr. Kin Hung Lee M.B.A. Sr. VP of Corp. Fin. & Devel. 1977
Mr. Charles George Rupert Nixon Group Gen. Counsel 1970
Ms. Selina Zhang Sr. VP of Global HR NA
Dr. Qingmei Wang Ph.D. Sr. VP of Bus. Devel. & Strategic Alliances 1963
Mr. Hong Chen Sr. VP & Chief Commercial Officer- China 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions